Product
Cenegemin
1 clinical trial
1 indication
Indication
Neurotrophic KeratopathyClinical trial
A Long-term Extension Study to Evaluate the Safety and Efficacy of OXERVATE 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis Who Enrolled in the DEFENDO StudyStatus: Recruiting, Estimated PCD: 2024-09-04